# Nuclide record alphabreak (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/alphabreak/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "alphabreak", "NCT06402331" ;
  schema:name "AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)"@en ;
  schema:description "The actinium-225 PSMA trials that will help decide whether alpha-emitting PSMA drugs become the next step after Pluvicto."@en ;
  schema:url <https://nuclide.cc/trials/alphabreak/> ;
  schema:dateModified "2026-09-27"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06402331> ;
  nuclide:status "active" ;
  nuclide:phase "2" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ac225-psma/> ;
  nuclide:companies <https://nuclide.cc/companies/fusion-pharma/>, <https://nuclide.cc/companies/astrazeneca/>, <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/bayer/> .